To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
CD&R-led investor group injects $100m into M2GEN, looking to transform cancer care with data
A crucial component of the transaction, CD&R's Sarah Kim says, was helping to reawaken the commercial relationship between pharmaceutical giant Merck and the data and informatics business.
